Connect with us

Technology

PCM Trials Acquires EmVenio Research to Create the Most Patient-Centric Model for Hybrid and Decentralized Clinical Trials

Published

on

EmVenio’s Community Research Site Network helps remove barriers for participation in clinical research for underrepresented communities

DENVER, Feb. 23, 2024 /PRNewswire/ — Denver-based PCM Trials, the largest independent mobile research nurse visit provider for decentralized clinical trials (DCTs), today announced the acquisition of EmVenio Research based in Durham, North Carolina. EmVenio is the largest provider of community-based clinical trial sites served with mobile research units. The acquisition, which is effective immediately, strengthens PCM Trials’ and EmVenio’s abilities to recruit and retain diverse populations for clinical research studies, as required for regulatory approval. Site networks are key to delivering critical study data for sponsors; by combining capabilities with EmVenio, PCM Trials now has access to a site network that is focused on serving underrepresented patient populations in previously hard-to-reach communities and can work flexibly with sponsors to achieve their study goals.

“The acquisition of EmVenio is an important part of our company’s overall strategy to further remove barriers for patients of all backgrounds and ethnicities to participate in clinical research, creating the most patient-centric clinical trial model,” said Greg Austin, President of PCM Trials. “Our pioneering approach to using Certified Mobile Research Nurses who visit patients in their homes has already been shown to improve both patient retention and diversity in clinical trials and drive faster study completion. Now, with the addition of EmVenio’s mobile research site network, we have the unmatched ability to provide additional convenience for prospective participants, empowering community-based clinical trial access.”

For years, regulatory bodies including the FDA have expressed concerns about the underrepresentation of minorities in clinical trials and have increased population diversity requirements for clinical research before approving new drugs. African Americans, for example, which make up 13.4% of the U.S. population only account for roughly 5% of trial participation, according to FDA data. The disparity for Hispanics and people of Latin origin is even greater, with Hispanics representing 18.1% of the U.S. population but only 1% of clinical trial participants. Merging the capabilities of PCM Trials and EmVenio creates a unique and powerful recruitment and visit model in underrepresented communities that effectively addresses and overcomes these challenges.

EmVenio has contracted 25 studies across numerous therapeutic areas. The company has activated 63 mobile sites for studies across 22+ U.S. states and 10 locations in the United Kingdom, thus garnering a wide demographic reach of diverse patients. EmVenio’s sites are seeing greater than 50% diverse patients across all locations compared with the industry average of less than 20%. With an impressive 96.9% retention rate, EmVenio is setting a new standard in the field.

“We are thrilled to announce the culmination of EmVenio’s and PCM Trials’ efforts in creating the most comprehensive global capability for patient visits, spanning from traditional site settings to the comfort of one’s home, and everywhere in between through mobile sites.” said Thad Wolfram, President of EmVenio. “Our combined services prioritize minimizing burdens for research participation while enhancing the overall participant experience.”

“It just makes sense that, if you can make it easier for patients to participate, you are also going to improve your recruitment and retention rates,” said Austin. “Many patients, especially those in underserved rural areas, travel two or more hours to get to a clinical site. This creates a tremendous burden for them, especially considering that many of them are sick or immobile or lack reliable childcare. By bringing into their homes a trained nurse who is often from the same neighborhood or a fully equipped mobile research unit into their neighborhood, you effectively eliminate many of the barriers that could have kept them from participating.”

This is the second acquisition completed by PCM Trials within the past month. On January 10, the company announced the acquisition of Netherlands-based Clinical Trial Service (CTS), which solidified PCM Trials’ ability and reach to successfully conduct global clinical trials.

“With these acquisitions, we are now the largest and most experienced clinical research local access provider on a global scale,” said Austin.

For more information about PCM Trials or to initiate an RFP for an upcoming trial, email info@pcmtrials.com.

About PCM Trials
PCM Trials is leading the global shift toward decentralized clinical trials by bringing clinical research to patients, wherever and whenever it is most convenient for them. PCM Trials directly recruits, trains, certifies, and manages Certified Mobile Research Nurses (CMRNs) to ensure that each visit meets the highest standards for data quality and patient experience. By reducing the barriers to participation, PCM Trials’ mobile nurses support study recruitment, retention, adherence, and diversity. PCM Trials is an independent company headquartered in Denver, Colorado with a European regional office located in the Netherlands and has conducted mobile research visits since 2008.

About EmVenio Research
EmVenio Research provides rapid and scalable mobile community research site solutions to better reach and recruit diverse, underserved and high-risk communities. EmVenio Research’s global network of skilled clinicians, principal investigators and state-of-the-art mobile community research sites enable them to provide robust clinical research services via home visits, on-site support at medical facilities, virtual visits and mobile sites. Visit emvenio.com to learn more.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pcm-trials-acquires-emvenio-research-to-create-the-most-patient-centric-model-for-hybrid-and-decentralized-clinical-trials-302070059.html

SOURCE PCM Trials

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

TiTE x IHT 2026: The Definitive Hub for Taiwan’s Hardware Manufacturing Excellence

Published

on

By

TAICHUNG, May 6, 2026 /PRNewswire/ — When sourcing from Taiwan, location is the ultimate strategic advantage. Don’t be misled by smaller, general trade shows held in city centers like Taipei. To truly connect with the source, you must go where the products are born. TiTE x IHT (Oct 20-22, 2026) in Taichung is the undisputed largest and most vital hardware industrial expo on the island. Hosted directly in the heart of Taiwan’s precision manufacturing cluster, this event features 1,000+ booths and 500+ top-tier manufacturers, offering a scale and industrial depth that no other exhibition can replicate.

Why Global Buyers Choose the Taichung Source Over Urban Trade Shows:

The Revolutionary “Exhibition as Factory” Model: Taichung is the global epicenter for hardware, home to 70% of Taiwan’s industry output. Our unique location enables the “30-Minute Sourcing Circle.” This allows you to verify high-end samples on the show floor in the morning and audit world-class production lines by the afternoon. By eliminating the travel gap between the booth and the factory, we reduce traditional procurement cycles from weeks to hours, providing unmatched transparency for R&D, capacity assessment, and quality control.ESG & CBAM Compliance for Western Markets: As the EU’s Carbon Border Adjustment Mechanism (CBAM) and global ESG mandates reshape trade, our exhibitors are already ahead of the curve. Discover CBAM-ready solutions and green manufacturing processes specifically designed to meet the strict sustainability requirements of the European and American markets. We provide more than just tools; we provide carbon-footprint-managed resilience for your brand.AI-Driven Smart Manufacturing: Address global labor shortages and rising costs with Taiwan’s latest innovations. The 2026 expo focuses on “AI Empowerment,” showcasing collaborative robotics, automated digital inspection, and data-driven supply chain management. These technologies ensure lead-time stability and high-precision consistency for premium global brand owners.Direct Sourcing & Global Matchmaking: Skip the middlemen and trading agencies. Our “Global Buyer Day” offers exclusive, pre-arranged matchmaking with the actual OEMs/ODMs. This is the primary decision-making platform for major distributors seeking resilient, direct-to-factory partnerships that guarantee the best pricing and priority production slots.

Experience the synergy of smart manufacturing and global trade. Stop at the source—where the world’s hardware is actually built. Secure your competitive edge in the true heart of the industry.

【TiTE x IHT】

Date: October 20-22, 2026Venue: TICEC, Taichung, TaiwanRegister Now: https://accu.ps/g8MZ1SHousing Subsidy: https://forms.gle/34VHVxSrEw7g8GxDAOfficial Website: https://www.hardwareexpotw.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/tite-x-iht-2026-the-definitive-hub-for-taiwans-hardware-manufacturing-excellence-302763625.html

SOURCE TiTE x IHT

Continue Reading

Technology

KIST Accelerates U.S. Expansion of Quantum Deep-Tech Startups Through SelectUSA 2026

Published

on

By

SEOUL, South Korea, May 5, 2026 /PRNewswire/ — The Korea Institute of Science and Technology (KIST) President Oh Sang-rok announced that it will participate in the SelectUSA Investment Summit 2026 as part of a Korean delegation, together with quantum technology startups supported by the Ministry of SMEs and Startups under the Deeptech Project (DIPS).

The initiative, supported by South Korea’s Ministry of SMEs and Startups (MSS), is part of the government’s “Deeptech Incubator Project for Startups” (DIPS) initiative, which aims to nurture globally competitive deep-tech ventures.

KIST, which serves as the lead institution for the quantum technology sector under the program, said it will oversee the global commercialization efforts of participating firms. In particular, the “Global Bridge Program,” jointly developed with the U.S. Embassy in Korea in September 2025, is an official program designed to generate tangible overseas expansion outcomes by linking investment attraction with local market entry through diplomatic channels.

Organized by the U.S. Department of Commerce, the SelectUSA Investment Summit is the largest investment promotion event in the US, connecting international startups with venture capital firms, corporate investors and state-level economic development agencies.

It serves as an execution-oriented platform that extends to investment, corporate establishment, site selection, and tax incentives, and is considered a key entry gateway for deep-tech companies, including those in quantum technology.

KIST said participation in the summit is particularly significant for deep-tech sectors such as quantum technology, where access to the US innovation ecosystem is seen as key to growth.

The program is conducted in two stages. From April 30 to May 1, companies took part in a spin-off program hosted by the State of Maryland, which included visits to research institutions and tours of the regional quantum technology ecosystem.

During this period, the delegation also conducted localized activities with the Maryland state government and its economic development agencies, focusing on investment attraction, corporate collaboration, and joint R&D. In addition, on May 5, the delegation held discussions with U.S. Department of Commerce Deputy Secretary William Kimmitt on potential areas of cooperation.

The delegation will also meet officials from Fairfax County Government to explore collaboration and investment opportunities.

The main summit, currently ongoing from May 3 to May 6, features exhibitions, pitching sessions and meetings with US state representatives, with participating firms expected to engage in discussions on investment and market entry.

The delegation is structured to encompass the entire quantum industry rather than a single technology domain.

The Korean delegation comprises five startups, alongside Kyung Hee University Department of Future Science & Technology Commercialization Policy and Entrepreneurship, with approximately 20 participants forming an integrated ecosystem that combines research institutes, academia, and startups, enabling a full-cycle support system from technology validation to commercialization and global expansion.

One of the firms, OptiQ-Labs, was selected for an official pitching session on May 4, where it presented its laser-based optical modules designed for ion-trap quantum computing systems.

This highly competitive program selects only around 100 companies from more than 20,000 applicants worldwide. If selected as the winner of the pitching session, the company will receive follow-up meetings with U.S. state governments and economic development agencies, access to global investor networks, support for local entity establishment, and connections to site selection and tax incentive programs.

Other participating companies include QUAD, which develops single-photon detection technology; SLEEX, focused on underwater sensing; Elixir (StatUp AI), which works on quantum-classical hybrid algorithms for healthcare; and SQK (QMEDIC), specializing in physics-based imaging solutions.

KIST Project Director, Kang Sunjoon, said, “This program represents a critical milestone for Korean quantum startups to directly connect with global investors and industry ecosystems. Via the DIPS program, we are actively promoting the global commercialization of quantum technologies.”

Through its participation in SelectUSA, KIST has established a package-type global expansion model that integrates technology validation, investment attraction, and U.S. market entry.

The summit serves as a turning point for South Korea’s quantum sector, enabling startups to move into the next phase of validation, investment, and overseas expansion.

For more information, visit https://eng.kist.re.kr/.

About KIST 

KIST was established in 1966 as the first government-funded research institute in South Korea. KIST now strives to solve national and social challenges and secure growth engines through leading and innovative research.

About Participating Quantum Startups

QUAD, led by Chief Executive Officer, Oh Byung-doo, develops quantum sensing technologies based on superconducting nanowire single-photon detectors (SNSPDs), offering high sensitivity and precision with applications spanning quantum communication, quantum computing, semiconductor inspection, and defense.

SLEEX is developing an advanced perception technology that combines quantum LiDAR and electric field sensing to overcome limitations of existing underwater sensors, particularly by eliminating blind zones within the 0–2 meter range, with strong potential in autonomous navigation, maritime security, and defense, with Lee Jeho at the helm as Chief Executive Officer.  (https://www.thesleex.com)

Elixir, headed by Chief Executive Officer Jang Jung-kwon, develops a drug discovery and biomarker analysis platform based on quantum-classical hybrid algorithms, targeting the precision medicine market through the integration of bioinformatics and quantum machine learning. (statupai.com)

SQK develops medical imaging AI based on quantum-physics constraints, addressing the hallucination issues of conventional AI by ensuring physical consistency in CT and MRI reconstruction. Under the leadership of Chief Executive Officer Kim Yoon-hak, SQK is improving reliability and reducing the need for re-scans in clinical settings. (www.sqkcloud.com)

View original content to download multimedia:https://www.prnewswire.com/news-releases/kist-accelerates-us-expansion-of-quantum-deep-tech-startups-through-selectusa-2026-302763636.html

SOURCE The Korea Institute of Science and Technology (KIST)

Continue Reading

Technology

Former Visa Asia Pacific Executive David Tay Joins YeahPay as Global Vice President

Published

on

By

SINGAPORE, May 6, 2026 /PRNewswire/ — YeahPay, the international payment brand under YEAHKA (9923.HK), has appointed David Tay, a former senior executive at Visa Asia Pacific, as Global Vice President, tasking him with overseeing the strategic direction and product ecosystem development of YEAHKA’s overseas payment business. The appointment comes as global digital trade enters a new phase defined by ecosystem integration, with payment infrastructure undergoing a generational shift in acceleration.

David Tay, a Singaporean national, is a rising leader in the payments industry. During his career at Visa, David played a key role in driving business growth across multiple Southeast Asian markets, demonstrating early promise in commercial insight and innovation. He subsequently moved into Visa’s Innovation division, where he rose to serve as Head of Innovation, leading Visa Pacific’s product innovation and new business.

In that capacity, David led the commercialization of cutting-edge payment paradigms including Visa Flex Credential and Pay by Palm. He was also involved in the evaluation and governance of strategic partners across the region, accumulating deep expertise in collaborating with banks, fintechs, and large-scale enterprise merchants.

David’s track record spans the full go-to-market lifecycle, from concept to pilot to scale, as well as deep capabilities in cross-institutional partnerships and ecosystem development. His appointment comes at an inflection point for YEAHKA’s international expansion. According to YEAHKA’s 2025 annual report, its overseas business delivered full-year Gross Payment Volume (GPV) surpassing RMB 5 billion, representing a 323.3% year-on-year surge from RMB 1.1 billion in 2024.

View original content:https://www.prnewswire.com/apac/news-releases/former-visa-asia-pacific-executive-david-tay-joins-yeahpay-as-global-vice-president-302763652.html

SOURCE Yeahka

Continue Reading

Trending